{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:05:19Z","timestamp":1745222719599},"reference-count":90,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this review, we provide an update on the status of cancer biomarkers for the clinical management of pleural mesothelioma, an aggressive cancer associated with asbestos exposure. Mesothelioma can be difficult to diagnose, and response to treatment is transient, even with recently adopted immune checkpoint inhibitor (ICI) combinations. Identification of mesothelioma-specific biomarkers could facilitate early diagnosis and tailor treatment strategies. Mesothelioma is characterized by frequent loss or alteration of the tumor suppressor genes cyclin-dependent kinase inhibitor 2A (CDKN2A) and BRCA1-associated protein-1 (BAP1). Accumulating data show these genes and\/or their related protein products will be valuable tissue-based biomarkers for mesothelioma. Loss of BAP1, CDKN2A, p16, or methylthioadenosine phosphorylase provide pathologists with a reliable means of differentiating between mesothelioma and reactive mesothelial cell proliferations. This can aid diagnosis in difficult cases and is requisite for the identification of the new pathological entity malignant mesothelioma in situ. However, limited progress in identifying clinically useful soluble biomarkers in this cancer type has been made, with mesothelin remaining the benchmark. To date, results from studies to identify predictive biomarkers for ICI response have been disappointing. A recent retrospective study demonstrated BAP1 loss was predictive of improved survival following combination pemetrexed- and platinum-based chemotherapy. Validation of this result could have important clinical implications. Clinical trials aimed at targeting therapy based on biomarker expression are generally in the early phase setting, with overall results being moderate. The identification of biomarkers for mesothelioma remains a key research question due to their potential to improve patient outcomes in this deadly cancer.<\/jats:p>","DOI":"10.1055\/s-0043-1769097","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T22:40:51Z","timestamp":1685486451000},"page":"491-501","source":"Crossref","is-referenced-by-count":4,"title":["New Markers for Management of Mesothelioma"],"prefix":"10.1055","volume":"44","author":[{"given":"Alistair","family":"Nash","sequence":"additional","affiliation":[{"name":"National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia"},{"name":"Medical School, University of Western Australia, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Firth n\u00e9e Phan","sequence":"additional","affiliation":[{"name":"National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia"},{"name":"Institute for Respiratory Health, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenette","family":"Creaney","sequence":"additional","affiliation":[{"name":"National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia"},{"name":"Medical School, University of Western Australia, Perth, Australia"},{"name":"Institute for Respiratory Health, Perth, Australia"},{"name":"Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"e2120360","DOI":"10.1001\/jamanetworkopen.2021.20360","article-title":"Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017","volume":"4","author":"Z Zhai","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"A W Musk","year":"2011","journal-title":"Eur Respir J"},{"issue":"S 01","key":"ref3","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.21037\/tlcr.2020.01.08","article-title":"Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma","volume":"9","author":"G A Woodard","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"N J Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"B W Robinson","year":"2003","journal-title":"Lancet"},{"issue":"S 01","key":"ref7","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"I Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"J Creaney","year":"2014","journal-title":"Dis Markers"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"S Popat","year":"2022","journal-title":"Ann Oncol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"A Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"B S Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCP.0000000000000578","article-title":"Advances in pathological diagnosis of mesothelioma: what pulmonologists should know","volume":"25","author":"A Louw","year":"2019","journal-title":"Curr Opin Pulm Med"},{"issue":"06","key":"ref13","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"P B Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref14","volume-title":"WHO Classification of Tumours: Thoracic Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2021","edition":"5th ed. Lyon, F"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.pathol.2020.12.005","article-title":"The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis","volume":"53","author":"S Klebe","year":"2021","journal-title":"Pathology"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jtho.2021.05.018","article-title":"Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases","volume":"16","author":"S Tsim","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"15","key":"ref17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"H I Pass","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"R M Ostroff","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"J Creaney","year":"2014","journal-title":"Thorax"},{"issue":"162","key":"ref20","doi-asserted-by":"crossref","first-page":"210057","DOI":"10.1183\/16000617.0057-2021","article-title":"Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"30","author":"E Schillebeeckx","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3892\/ol.2021.12783","article-title":"Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma","volume":"22","author":"M Kanayama","year":"2021","journal-title":"Oncol Lett"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/JTO.0000000000000181","article-title":"Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee","volume":"9","author":"H I Pass","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"D Curran","year":"1998","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"J E Herndon II","year":"1998","journal-title":"Chest"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"S Dacic","year":"2008","journal-title":"Virchows Arch"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5858\/arpa.2021-0331-OA","article-title":"A combination of MTAP and p16 immunohistochemistry can substitute for CDKN2A fluorescence in situ hybridization in diagnosis and prognosis of pleural mesotheliomas","volume":"147","author":"L Brcic","journal-title":"Arch Pathol Lab Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","article-title":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","volume":"60","author":"S M McGregor","year":"2017","journal-title":"Hum Pathol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"F L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"J Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"M Farzin","year":"2015","journal-title":"Pathology"},{"issue":"06","key":"ref32","first-page":"1010428317699111","article-title":"Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer","volume":"39","author":"X Y Wang","year":"2017","journal-title":"Tumour Biol"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"A Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1310478","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"E Pulford","year":"2017","journal-title":"Dis Markers"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/dc.23837","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions","volume":"46","author":"I Cozzi","year":"2018","journal-title":"Diagn Cytopathol"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"F Forest","year":"2018","journal-title":"Pathology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","article-title":"Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis","volume":"146","author":"L Cantini","year":"2020","journal-title":"Lung Cancer"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"J R Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2014.10.017","article-title":"Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases","volume":"87","author":"A Rusch","year":"2015","journal-title":"Lung Cancer"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"F Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"35","key":"ref42","doi-asserted-by":"crossref","first-page":"JCO2018790352","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"S Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"ref43","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"R Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.13392","article-title":"The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma","volume":"72","author":"A Chou","year":"2018","journal-title":"Histopathology"},{"issue":"28","key":"ref45","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"L Tian","year":"2017","journal-title":"Oncotarget"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"K Hollevoet","year":"2012","journal-title":"Chest"},{"issue":"02","key":"ref47","first-page":"145","article-title":"The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma","volume":"5","author":"T Mori","year":"2013","journal-title":"J Thorac Dis"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"M B Kirschner","year":"2015","journal-title":"Br J Cancer"},{"issue":"08","key":"ref49","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis","volume":"8","author":"D Pei","year":"2017","journal-title":"Oncotarget"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","article-title":"Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition","volume":"10","author":"B Ghanim","year":"2020","journal-title":"Sci Rep"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1245\/s10434-018-6385-x","article-title":"The C-reactive protein\/albumin ratio is a novel significant prognostic factor in patients with malignant pleural mesothelioma: a retrospective multi-institutional study","volume":"25","author":"S Takamori","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"101813","DOI":"10.1016\/j.suronc.2022.101813","article-title":"Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy","volume":"43","author":"R Okita","year":"2022","journal-title":"Surg Oncol"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/MCG.0b013e318297fa65","article-title":"Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma","volume":"47","author":"C Tabata","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"N Hirayama","year":"2011","journal-title":"Respir Med"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/biom10081113","article-title":"Multiplex soluble biomarker analysis from pleural effusion","volume":"10","author":"J Javadi","year":"2020","journal-title":"Biomolecules"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"J Creaney","year":"2013","journal-title":"Lung Cancer"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12890-022-01968-2","article-title":"Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma","volume":"22","author":"D De Fonseka","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"S Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study","volume":"10","author":"L Brcic","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"M Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"718675","DOI":"10.3389\/fphar.2021.718675","article-title":"Upregulation of thymidylate synthase induces pemetrexed resistance in malignant pleural mesothelioma","volume":"12","author":"Y Sato","year":"2021","journal-title":"Front Pharmacol"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"P A Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"7","author":"D C Christoph","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"04","key":"ref64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","article-title":"Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma","volume":"8","author":"D E Lustgarten","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/JTO.0b013e318287c224","article-title":"Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma","volume":"8","author":"F Mairinger","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"A Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"M J Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00262-018-2258-1","article-title":"Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study","volume":"68","author":"M P Pistillo","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00005-021-00618-5","article-title":"CTLA-4 expression and its clinical significance in breast cancer","volume":"69","author":"R Kern","year":"2021","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"D A Fennell","year":"2022","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref71","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression","volume":"15","author":"D Rathkey","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"M G Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"D A Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"237","key":"ref74","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"I M Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"issue":"10","key":"ref75","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"G Mak","year":"2019","journal-title":"Br J Cancer"},{"issue":"10","key":"ref76","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-a double-blind, randomized, phase II study","volume":"37","author":"D A Fennell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"208","key":"ref77","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"R Hassan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"21","key":"ref78","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"R Hassan","year":"2014","journal-title":"Cancer"},{"issue":"04","key":"ref80","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"H L Kindler","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref81","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"J Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial","volume":"5","author":"R Hassan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"03","key":"ref83","first-page":"100135","article-title":"Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study","volume":"2","author":"N Fujimoto","year":"2020","journal-title":"JTO Clin Res Rep"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"L Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"09","key":"ref85","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"A K Nowak","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"ref86","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"D A Fennell","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref87","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"S Popat","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"ref88","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"P M Forde","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"ref89","first-page":"100231","article-title":"Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"A Ghafoor","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa Trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors","volume":"28","author":"S Rottey","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"ref91","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"P S Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"19","key":"ref92","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma","volume":"25","author":"R Hassan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"08","key":"ref93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1200\/JCO.2019.37.8_suppl.29","article-title":"A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM)","volume":"37","author":"E W Alley","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1769097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T23:56:27Z","timestamp":1689033387000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1769097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":90,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,7,10]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1769097","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]}}}